Details of the Drug

General Information of Drug (ID: DMK8AQP)

Drug Name

Sirukumab

Indication

Disease Entry	ICD 11	Status	REF
Cutaneous lupus erythematosus	EB5Z	Phase 3	[1]
Giant cell arteritis	4A44.2	Phase 3	[2]
Rheumatoid arthritis	FA20	Phase 3	[3]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[4]
Major depressive disorder	6A70.3	Phase 2	[5]
------------------------------------------------------------------------------------

ATC Code

L04AC15: Sirukumab

L04AC: Interleukin inhibitors

L04A: IMMUNOSUPPRESSANTS

L04: IMMUNOSUPPRESSANTS

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Type

Monoclonal antibody

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 6 receptor (IL6R)	TT0E5SK	IL6RA_HUMAN ; IL6RB_HUMAN	Not Available	[6]
Interleukin-6 (IL6)	TTT1V78	IL6_HUMAN	Inhibitor	[2]
HUMAN interleukin 6 (IL6)	TTJH4Y5	IL6_HUMAN	Inhibitor	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Cutaneous lupus erythematosus

ICD Disease Classification

EB5Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Interleukin 6 receptor (IL6R)	DTT	IL6R; IL6ST	1.13E-04	1.32	1.28

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT01856309) Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	ClinicalTrials.gov (NCT01689532) A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine. U.S. National Institutes of Health.
4	ClinicalTrials.gov (NCT04380961) A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19. U.S. National Institutes of Health.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310).
7	Sirukumab: A Potential Treatment for Mood Disorders Adv Ther. 2017 Jan;34(1):78-90.